-
PRISM2: Unlocking Multi-Modal General Pathology AI with Clinical Dialogue
Authors:
George Shaikovski,
Eugene Vorontsov,
Adam Casson,
Julian Viret,
Eric Zimmermann,
Neil Tenenholtz,
Yi Kan Wang,
Jan H. Bernhard,
Ran A. Godrich,
Juan A. Retamero,
Razik Yousfi,
Nicolo Fusi,
Thomas J. Fuchs,
Kristen Severson,
Siqi Liu
Abstract:
Recent pathology foundation models can provide rich tile-level representations but fall short of delivering general-purpose clinical utility without further extensive model development. These models lack whole-slide image (WSI) understanding and are not trained with large-scale diagnostic data, limiting their performance on diverse downstream tasks. We introduce PRISM2, a multi-modal slide-level f…
▽ More
Recent pathology foundation models can provide rich tile-level representations but fall short of delivering general-purpose clinical utility without further extensive model development. These models lack whole-slide image (WSI) understanding and are not trained with large-scale diagnostic data, limiting their performance on diverse downstream tasks. We introduce PRISM2, a multi-modal slide-level foundation model trained via clinical dialogue to enable scalable, generalizable pathology AI. PRISM2 is trained on nearly 700,000 specimens (2.3 million WSIs) paired with real-world clinical diagnostic reports in a two-stage process. In Stage 1, a vision-language model is trained using contrastive and captioning objectives to align whole slide embeddings with textual clinical diagnosis. In Stage 2, the language model is unfrozen to enable diagnostic conversation and extract more clinically meaningful representations from hidden states. PRISM2 achieves strong performance on diagnostic and biomarker prediction tasks, outperforming prior slide-level models including PRISM and TITAN. It also introduces a zero-shot yes/no classification approach that surpasses CLIP-style methods without prompt tuning or class enumeration. By aligning visual features with clinical reasoning, PRISM2 improves generalization on both data-rich and low-sample tasks, offering a scalable path forward for building general pathology AI agents capable of assisting diagnostic and prognostic decisions.
△ Less
Submitted 15 June, 2025;
originally announced June 2025.
-
Screen Them All: High-Throughput Pan-Cancer Genetic and Phenotypic Biomarker Screening from H&E Whole Slide Images
Authors:
Yi Kan Wang,
Ludmila Tydlitatova,
Jeremy D. Kunz,
Gerard Oakley,
Ran A. Godrich,
Matthew C. H. Lee,
Chad Vanderbilt,
Razik Yousfi,
Thomas Fuchs,
David S. Klimstra,
Siqi Liu
Abstract:
Many molecular alterations serve as clinically prognostic or therapy-predictive biomarkers, typically detected using single or multi-gene molecular assays. However, these assays are expensive, tissue destructive and often take weeks to complete. Using AI on routine H&E WSIs offers a fast and economical approach to screen for multiple molecular biomarkers. We present a high-throughput AI-based syst…
▽ More
Many molecular alterations serve as clinically prognostic or therapy-predictive biomarkers, typically detected using single or multi-gene molecular assays. However, these assays are expensive, tissue destructive and often take weeks to complete. Using AI on routine H&E WSIs offers a fast and economical approach to screen for multiple molecular biomarkers. We present a high-throughput AI-based system leveraging Virchow2, a foundation model pre-trained on 3 million slides, to interrogate genomic features previously determined by an next-generation sequencing (NGS) assay, using 47,960 scanned hematoxylin and eosin (H&E) whole slide images (WSIs) from 38,984 cancer patients. Unlike traditional methods that train individual models for each biomarker or cancer type, our system employs a unified model to simultaneously predict a wide range of clinically relevant molecular biomarkers across cancer types. By training the network to replicate the MSK-IMPACT targeted biomarker panel of 505 genes, it identified 80 high performing biomarkers with a mean AU-ROC of 0.89 in 15 most common cancer types. In addition, 40 biomarkers demonstrated strong associations with specific cancer histologic subtypes. Furthermore, 58 biomarkers were associated with targets frequently assayed clinically for therapy selection and response prediction. The model can also predict the activity of five canonical signaling pathways, identify defects in DNA repair mechanisms, and predict genomic instability measured by tumor mutation burden, microsatellite instability (MSI), and chromosomal instability (CIN). The proposed model can offer potential to guide therapy selection, improve treatment efficacy, accelerate patient screening for clinical trials and provoke the interrogation of new therapeutic targets.
△ Less
Submitted 20 August, 2024; v1 submitted 18 August, 2024;
originally announced August 2024.
-
Virchow: A Million-Slide Digital Pathology Foundation Model
Authors:
Eugene Vorontsov,
Alican Bozkurt,
Adam Casson,
George Shaikovski,
Michal Zelechowski,
Siqi Liu,
Kristen Severson,
Eric Zimmermann,
James Hall,
Neil Tenenholtz,
Nicolo Fusi,
Philippe Mathieu,
Alexander van Eck,
Donghun Lee,
Julian Viret,
Eric Robert,
Yi Kan Wang,
Jeremy D. Kunz,
Matthew C. H. Lee,
Jan Bernhard,
Ran A. Godrich,
Gerard Oakley,
Ewan Millar,
Matthew Hanna,
Juan Retamero
, et al. (6 additional authors not shown)
Abstract:
The use of artificial intelligence to enable precision medicine and decision support systems through the analysis of pathology images has the potential to revolutionize the diagnosis and treatment of cancer. Such applications will depend on models' abilities to capture the diverse patterns observed in pathology images. To address this challenge, we present Virchow, a foundation model for computati…
▽ More
The use of artificial intelligence to enable precision medicine and decision support systems through the analysis of pathology images has the potential to revolutionize the diagnosis and treatment of cancer. Such applications will depend on models' abilities to capture the diverse patterns observed in pathology images. To address this challenge, we present Virchow, a foundation model for computational pathology. Using self-supervised learning empowered by the DINOv2 algorithm, Virchow is a vision transformer model with 632 million parameters trained on 1.5 million hematoxylin and eosin stained whole slide images from diverse tissue and specimen types, which is orders of magnitude more data than previous works. The Virchow model enables the development of a pan-cancer detection system with 0.949 overall specimen-level AUC across 17 different cancer types, while also achieving 0.937 AUC on 7 rare cancer types. The Virchow model sets the state-of-the-art on the internal and external image tile level benchmarks and slide level biomarker prediction tasks. The gains in performance highlight the importance of training on massive pathology image datasets, suggesting scaling up the data and network architecture can improve the accuracy for many high-impact computational pathology applications where limited amounts of training data are available.
△ Less
Submitted 17 January, 2024; v1 submitted 14 September, 2023;
originally announced September 2023.